Y-90 Treatment (Radioembolization)
Updated: 3 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Y-90 treatment, also known as radioembolization, is a minimally invasive radiation therapy designed to treat primary and metastatic liver cancer. By injecting millions of microscopic radioactive beads directly into the blood vessels supplying a tumor, the procedure delivers high-dose radiation while sparing healthy liver tissue. This targeted approach shrinks tumors, improves quality of life, and can significantly extend life expectancy for patients with non-operable liver cancer.
Quick Answer
Y-90 treatment, or radioembolization, is a form of internal radiation therapy that uses radioactive Yttrium-90 beads to destroy liver tumors. An interventional radiologist delivers the microscopic beads through a catheter directly to the tumor, where they block its blood supply and release targeted radiation [1]. It suits patients who cannot have surgery and offers faster recovery than external radiation.
What the research says
Y-90 and chemoembolization perform similarly for survival, with fewer side effects. A meta-analysis of 4 randomized trials in 169 patients with early to intermediate stage hepatocellular carcinoma found no significant difference between Y-90 radioembolization and TACE in progression-free survival (HR 0.72, 95% CI 0.43–1.20) or overall survival (HR 0.82, 95% CI 0.49–1.35), while Y-90 caused significantly fewer treatment-related adverse events (OR 0.38, 95% CI 0.19–0.75) (Mirza et al., World J Surg Oncol, 2026) [2].
One randomized trial showed longer tumor control and survival with Y-90. In the TRACE phase II trial of 72 patients with early or intermediate stage hepatocellular carcinoma, median time to tumor progression was 17.1 months with Y-90 versus 9.5 months with drug-eluting bead chemoembolization, and median overall survival was 30.2 versus 15.6 months, with similar rates of serious adverse events (Dhondt et al., Radiology, 2022) [3].
Y-90 can help bridge or downstage patients for liver transplant. A meta-analysis of 12 studies including 10,661 patients found downstaging rates were similar for Y-90 and TACE (OR 0.96, 95% CI 0.60–1.54), while Y-90 needed fewer treatment sessions and caused less grade 3/4 bilirubin toxicity (OR 0.32, 95% CI 0.11–0.91) (Xie and Zhen, Cardiovasc Intervent Radiol, 2026) [4].
What is Y-90 treatment (radioembolization)?
Y-90 treatment is a sophisticated interventional radiology procedure used in oncology, focused on the internal delivery of radiation. The name "Y-90" refers to Yttrium-90, a radioactive isotope that emits high-energy beta radiation. Unlike external beam radiation therapy (EBRT), which directs radiation from a machine outside the body, Y-90 therapy is performed internally. This allows for a much higher dose of radiation to be concentrated exactly where it is needed—within the liver tumor itself [1].
The procedure is particularly effective for liver tumors because the liver has a unique dual blood supply. Healthy liver tissue receives most of its blood from the portal vein, while liver tumors primarily draw blood from the hepatic artery. By injecting the Y-90 beads into the hepatic artery, physicians can ensure that the majority of the radiation reaches the cancerous cells, leaving the healthy parts of the liver largely unaffected.
Types of Radioembolization
While the procedure is most commonly referred to as Y-90 treatment, it is known by several other clinical names depending on the specific technique and materials used.
Term | Full Name | Description |
TARE | Transarterial Radioembolization | Focuses on the arterial route used to deliver the radioactive beads. |
SIRT | Selective Internal Radiation Therapy | Emphasizes the selective nature of the radiation delivery to the tumor. |
Radioembolization | N/A | A general term combining "radiation" and "embolization" (blocking blood flow). |
How does the Y-90 radioembolization process work?
Y-90 therapy is not a single event but a multi-stage process that typically involves two main procedures performed about two weeks apart. Both procedures are led by an interventional radiologist and are minimally invasive, requiring only a tiny incision in the groin or wrist [1].
The first stage is the Mapping Angiogram. This "test run" allows the care team to visualize the complex network of blood vessels supplying the tumor. By injecting a contrast dye and using real-time X-ray imaging, the radiologist can map the exact route the beads must take [1]. This ensures that the radiation will be delivered safely and accurately during the actual treatment.
The second stage is the Y-90 Infusion. Following the same path mapped during the angiogram, the radiologist threads a catheter to the tumor site and injects millions of microscopic glass or plastic beads. These beads, each about the size of a grain of powdered sugar, become lodged in the small vessels of the tumor. Once in place, they release 90% of their radiation over the first 10 days [1], gradually decaying into a safe, inactive state while remaining permanently in the body.
What are the benefits and success rates of Y-90 radioembolization?
The primary benefit of Y-90 treatment is its ability to deliver aggressive radiation therapy with minimal systemic side effects. Because the radiation travels less than half an inch from the beads [1], patients avoid the skin damage of external radiation, although tiredness for a week or two is common. Additionally, the minimally invasive nature of the procedure means that most patients can return home the same day [1] and avoid the long recovery times required by open surgery.
For many patients with non-operable liver cancer, Y-90 treatment is a life-extending intervention. Clinical data indicates that the therapy can increase life expectancy from just a few months to two or three years [1]. In some cases, the shrinking of the tumor may even make a patient eligible for curative treatments like a liver transplant or surgical resection [1].
Recovery and Aftercare
Recovery from Y-90 treatment is generally rapid, though patients should expect a period of adjustment as the radiation works within the liver.
Timeframe | Typical Experience |
First 5 Hours | Monitoring in the hospital to ensure vitals are stable and there is no bleeding. |
First 3 Days | Potential onset of Post-Embolization Syndrome (PES), including nausea and low-grade fever. |
Weeks 1–2 | Common feelings of fatigue as the body processes the radiation and the tumor reacts. |
Long-Term | Regular follow-up appointments and imaging to monitor tumor response and liver function. |
What are the risks and complications of Y-90 radioembolization?
Y-90 treatment complications are rare, and the most common side effect is post-embolization syndrome, which can cause temporary abdominal pain, appetite loss and nausea [1]. The most common side effect is Post-Embolization Syndrome (PES), which can cause temporary abdominal pain, loss of appetite, and nausea [1]. More serious, though less frequent, risks include infection at the catheter site, allergic reactions to the contrast dye [1], or the accidental migration of beads to the stomach or lungs, which can cause ulcers or inflammation. In rare cases, the treatment can lead to liver failure if the healthy tissue is excessively affected.
Conclusion
Y-90 treatment represents a significant advancement in the targeted management of liver cancer. By combining the precision of interventional radiology with the power of internal radiation, it provides a powerful alternative for patients who have limited surgical options. While it is not a cure on its own [1], its ability to control tumor growth and improve quality of life makes it a cornerstone of modern liver cancer care. If you are exploring treatment options for liver cancer, discuss with your oncology team whether Y-90 therapy is a suitable component of your comprehensive care plan.
Frequently Asked Questions
What does "Y-90" stand for?
Y-90 is short for Yttrium-90, which is the radioactive isotope used in the microscopic beads to treat liver tumors.
Is Y-90 treatment a cure for liver cancer?
Y-90 is not typically a cure on its own, but it is highly effective at shrinking tumors, slowing cancer progression, and improving quality of life.
How are the radioactive beads delivered to the liver?
The beads are delivered through a thin catheter that is threaded through an artery in the groin or wrist directly to the blood vessels supplying the tumor.
What is the purpose of the mapping angiogram?
The mapping angiogram is a preliminary procedure used to visualize the blood vessels and plan the safest, most accurate route for the radioactive beads.
How long does the radiation stay active in the body?
The Y-90 beads release approximately 90% of their radiation during the first 10 days after the infusion and slowly decay thereafter.
Can I go home the same day as the procedure?
Yes, most patients are monitored for a few hours after the treatment and are able to go home the same day.
What is Post-Embolization Syndrome (PES)?
PES is a common set of side effects following Y-90 treatment, including nausea, vomiting, belly pain, and a low-grade fever.
How much can Y-90 treatment extend life expectancy?
For non-operable liver cancer, Y-90 can extend life expectancy from a few months to up to two or three years.
What happens to the beads after they stop being radioactive?
The decayed beads remain safely and permanently lodged in the liver tissue and do not need to be removed.
How do I prepare for Y-90 treatment?
You will have a physical exam, blood tests and liver function tests to confirm you are healthy enough for treatment. [1] At a pre-procedure visit, your team reviews your medical history, allergies and possible pregnancy, discusses whether to stop any medicines, and tells you when to stop eating and drinking. Arrange support, such as someone to drive you home. [1]
Does Y-90 treatment hurt, and what anesthesia is used?
You receive a numbing medicine at the catheter site and a sedative to help you relax. [1] You may feel a quick sting or burning when the numbing medicine is injected and slight discomfort while the catheter and beads are placed. Afterward, belly pain from inflammation is common, and your provider can give you pain medicine. [1]
When should I call my doctor after the treatment?
You should contact your healthcare provider if you experience severe abdominal pain, signs of infection at the incision site, or persistent high fever.
Related Reading
References
Cleveland Clinic. Y-90 Treatment. Cleveland Clinic. Last updated May 1, 2025. https://my.clevelandclinic.org/health/procedures/y90-treatment-radioembolization
Mirza W, Khan ZA, Bhatti ABH. Transarterial radioembolization versus transarterial chemoembolization for tumor control and survival outcomes in early to intermediate stage hepatocellular carcinoma: systematic review and meta-analysis. World J Surg Oncol. 2026;24(1). PMID 42050547. https://doi.org/10.1186/s12957-026-04380-w
Dhondt E, Lambert B, Hermie L, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699-710. PMID 35258371. https://doi.org/10.1148/radiol.211806
Xie M, Zhen Y. Efficacy of transarterial radioembolization and transarterial chemoembolization as downstaging or bridging strategies for hepatocellular carcinoma before liver transplantation: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2026;49(9):1667-1679. PMID 41706092. https://doi.org/10.1007/s00270-026-04379-6
Medical disclaimer
The information provided in this article is for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Comments